Sander Slootweg, Forbion

Dri­ven by Covid-19 fever, For­bion notes in­vestor in­ter­est in vac­cines and new ther­a­pies as part of $557M fund

Near­ly a year in­to the Covid-19 pan­dem­ic, a wave of in­vest­ment in nov­el ther­a­pies and vac­cines to fight the virus has con­tin­ued to flow—and in­vestors are tak­ing no­tice.

De­spite fo­cus­ing most of its strat­e­gy on late-stage as­sets, For­bion has seen grow­ing in­ter­est from in­vestors in its $557 mil­lion Fund V in “nov­el med­i­cines, vac­cines and biotech so­lu­tions” to tack­le COVID-19, the Eu­ro VC firm said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.